BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 176
- Registration Number
- NCT01031459
Xarelto Regulatory Post-Marketing Surveillance
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Rivaroxaban (Xarelto, BAY59-7939)Drug: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3388
- Registration Number
- NCT01029743
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY79-4620
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01028755
Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain
Phase 3
Completed
- Conditions
- Low Back Pain
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 338
- Registration Number
- NCT01028079
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Phase 3
Completed
- Conditions
- Blood Coagulation DisordersHemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)Biological: Recombinant Factor VIII (BAY81-8973)
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 74
- Registration Number
- NCT01029340
- Locations
- 🇸🇪
Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT01021436
Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo
Phase 2
Completed
- Conditions
- Tinea Pedis
- Interventions
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT01013909
Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation
Phase 1
Completed
- Conditions
- QTc EvaluationElectrocardiography
- Interventions
- Drug: Avelox (Moxifloxacin, BAY12-8039)Drug: Placebo
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT01014247
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Phase 3
Completed
- Conditions
- Retinal Vein Occlusion
- Interventions
- Other: Sham treatmentBiological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 177
- Registration Number
- NCT01012973
Regulatory Post Marketing Surveillance Study on Nexavar®
Completed
- Conditions
- Carcinoma, Renal CellCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2845
- Registration Number
- NCT01012011
© Copyright 2025. All Rights Reserved by MedPath